StonvexLoading…
StonvexStonvexStonvexCore line items from TXMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $800.00K | $853.00K | $416.00K | $69.96M |
Operating Income | $-6.91M | $-5.14M | $-2.67M | $1.19M |
Net Income | $-9.39M | $-6.02M | $-3.60M | $112.00M |
EPS (Diluted) | $-0.92 | $-0.60 | $-0.37 | $11.96 |
Total Assets | $50.49M | $53.69M | $59.60M | $90.46M |
Total Liabilities | $22.44M | $22.49M | $27.58M | $55.31M |
Cash & Equivalents | $49.32M | $13.73M | $49.32M | $49.32M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 10.57M | 10.57M | 9.55M | 9.50M |